Switzerland· 69588002
Imaavy 1200 mg/6.5 ml (185 mg/ml), Konzentrat zur Herstellung einer Infusionslösung
A nipocalimab product containing nipocalimabum, registered in Switzerland by Janssen-Cilag AG and dispensed under Swissmedic category A. The same ATC class is registered in 8 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Nipocalimab is registered in 8 of 19 countries.
Countries holding a registration under ATC L04AL03 (nipocalimab), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 6 of them publish a price we can compare per daily dose
Nipocalimab · ATC L04AL03
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Switzerlandprice
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- nipocalimabum
- Manufacturer
- Janssen-Cilag AG
- Country
- Switzerland (CH)
- ATC code
- L04AL03
- ATC class
- Nipocalimab
- Swissmedic category
- A
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nipocalimab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesIMAAVYJanssen Biotech, Inc.
- CzechiaIMAAVYJanssen-Cilag International N.V., Beerse
- BelgiumImaavy 185 mg/mlJanssen-Cilag International
- Japanニポカリマブ（遺伝子組換え）ヤンセンファーマ
- FinlandImaavyJanssen Cilag International
- IrelandImaavy 185 mg/mL concentrate for solution for infusionJanssen-Cilag International NV
- IcelandIMAAVYJanssen Cilag International
- NetherlandsImaavy 185 mg/ml concentraat voor oplossing voor infusieJanssen-Cilag International NV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Imaavy
- Liechtenstein · Imaavy
- Norway · Imaavy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/38627aeb-db94-448e-8c3a-21fec8beaef5 GET /v1/drugs/38627aeb-db94-448e-8c3a-21fec8beaef5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Biotechnologika"
}See everything about nipocalimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.